insights_auto
Why is ATYR down 2.35%?
Dive Deeperchevron_right
ATYR:NASDAQ
aTyr Pharma Inc
$0.29
arrow_downward
-2.35%(-0.0069) 1D
$0.29
arrow_downward
-0.38% (-0.0011)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ATYR...
Open
$0.29
High
$0.30
Low
$0.28
Mkt. cap
28.57M
Avg. vol.
5.69M
Volume
1.96M
52-wk high
$1.12
52-wk low
$0.27
EPS
-$0.62
Beta
0.91
Shares outstanding
98.09M
No. of employees
59
Open
$0.29
High
$0.30
Low
$0.28
Mkt. cap
28.57M
Avg. vol.
5.69M
Volume
1.96M
52-wk high
$1.12
52-wk low
$0.27
EPS
-$0.62
Beta
0.91
Shares outstanding
98.09M
No. of employees
59
News stories
From web sources and news partners
Intellia Therapeutics
·
21 minutes ago
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance UK
·
22 minutes ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WSJ
·
3 days ago
Oura Postpones IPO Over Market Uncertainty
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc